Spanish Translations (Argentinian version)

Neurology® 2017; Vol. 88

Quality improvement in neurology: Dementia management quality measurement set update, Sanders et al. 88(20): 1951-1957.

Superficial brain stimulation to overcome freezing of gait in Parkinson disease, Nonnekes et al. 88(17): 1681-1682.

Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society, Harden et al. 88(17): 1674-1680.

Predominantly myalgic phenotype caused by the c.3466G>A p.A1156T mutation in SCN4A gene, Palmio et al. 88(16): 1520-1527.

ED misdiagnosis of cerebrovascular events in the era of modern neuroimaging: A meta-analysis">ED misdiagnosis of cerebrovascular events in the era of modern neuroimaging: A meta-analysis, Tarnutzer et al. 88(15): 1468-1477.

Diagnostic errors in cerebrovascular disease: What are we missing?, Batra et al. 88(15): 1390-1391.

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder, Hansson et al. 88(10):930-937.

Sulfonylurea receptor–associated channels: Involvement in disease and therapeutic implications, Benarroch. 88 (3): 314-321.
 

Neurology® 2016; Vol. 87

A neurodevelopmental approach to cognitive and behavioral assessment in epilepsy, Barr et al. 87(16):1634-1635.

Mechanisms of memory impairment in epilepsy depend on age at disease onset, Rayner et al. 87(16):1642-1649.

Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up, Sonderen et al. 87(14):1449-1456.

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia, Rohrer et al. 87(13):1329-1336.

Role of sleep-disordered breathing and sleep-wake disturbances for stroke and stroke recovery, Hermann et al. 88(13):1407-1416.

 

Neurology® 2016; Vol. 86

Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI, Landau et al. 86(15):1377-1385.

Zika virus: What the neurologist wants to know, Birbeck 86(14):1272-1274.

Statin therapy in acute ischemic stroke: Time for large randomized trials?, Charidimou and Merwick 86(12):1082-1083.

Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke, Tsivgoulis et al. 86(12):1103-1111.

Dorsal horn circuitry: Complexity and implications for mechanisms of neuropathic pain, Benarroch 86(11):1060-1069.

3,4-Diaminopyridine may improve myasthenia gravis with MUSK antibodies, Evoli et al. 86(11):1070-1071.

Pseudotumoral presentation of cerebral amyloid angiopathy–related inflammation, Ronsin et al. 86(10):912-919.

Orthostatic tremor: Clinical, electrophysiologic, and treatment findings in 184 patients, Hassan et al. 86(5):458-464.

Sodium channel Na_v1.8: Emerging links to human disease, Han et al. 86(5):473-483.

 

Neurology® 2015; Vol. 85

Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology, Halperin et al. 85(23):2063-2071.

Electrophysiologic features of SYT2 mutations causing a treatable neuromuscular syndrome, Whittaker et al. 85(22):1964-1971.

Autoimmune post–herpes simplex encephalitis of adults and teenagers, Armangue et al. 85(20):1736-1743.

Acute headache diagnosis in pregnant women: A hospital-based study, Robbins et al. 85(12):1024-1030.

Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: A randomized trial, French et al. 85(11):950-957.

The unruptured intracranial aneurysm treatment score: A multidisciplinary consensus, Etminan et al. 85(10):881-889.

Role of combined B-mode and Doppler sonography in evaluating neurolymphomatosis, Vijayan et al. 85(9):752-755.

Statin treatment reduces the risk of poststroke seizures, Guo et al. 85(8):701-707.

Temporal trends in safety of carotid endarterectomy in asymptomatic patients: Systematic review, Munster et al. 85(4):365-372.

Sudden cardiac arrest in people with epilepsy in the community: Circumstances and risk factors, Lamberts et al. 85(3):212-218.

Memory, executive, and multidomain subtle cognitive impairment: Clinical and biomarker findings, Toledo et al. 85(2):144-153.

 

Neurology® 2015; Vol. 84

Acquired axonal degeneration and regeneration: Recent insights and clinical correlations, Benarroch. 84(20):2076-2085.

Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy, Gidal et al. 84(19):1972-1980.

Neuronal Na⁺/K⁺ ATPase is an autoantibody target in paraneoplastic neurologic syndrome, Scharf et al. 84(16):1673-1679.

Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society, Krumholz et al. 84(16):1705-1713.

Recurrence of reversible cerebral vasoconstriction syndrome: A long-term follow-up study, Chen et al. 84(15):1552-1558.

Nuclear actin aggregation is a hallmark of anti-synthetase syndrome–induced dysimmune myopathy, Stenzel et al. 84(13):1346-1354.

Ion channels in nociceptors: Recent developments, Benarroch. 84(11):1153-1164.

Clinicopathologic features of folate-deficiency neuropathy, Koike et al. 84(10):1026-1033.

The amygdala: Functional organization and involvement in neurologic disorders, Benarroch. 84(3):313-324.

Metabolomics predicts stroke recurrence after transient ischemic attack, Jové et al. 84(1):36-45.

Optimal combination secondary prevention drug treatment and stroke outcomes, Park and Ovbiagele. 84(1):50-56.

Complex regional pain syndrome: An optimistic perspective, Birklein et al. 84(1):89-96.

 

Neurology® 2014; Vol. 83

Posterior reversible encephalopathy syndrome with spinal cord involvement, de Havenon et al. 83(22):2002-2006.

Small strokes causing severe vertigo: Frequency of false-negative MRIs and nonlacunar mechanisms, Saber Tehrani et al. 83(2):169-173.

Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome, Sawai et al. 83(2):113-117.

 

Neurology® 2014; Vol. 82

Peripheral hypoxia in restless legs syndrome (Willis-Ekbom disease), Salminen et al. 82(21):1856-1861.

Immune therapy for pharmacoresistant epilepsy: Ready to go?, Rüegg and Panzer 82(18):1572-1573.

Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy, Toledano et al. 82(18):1578-1586.

Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease, Kotagal et al. 82(17):1514-1520.

Progressive encephalomyelitis with rigidity and myoclonus: A new variant with DPPX antibodies, Balint et al. 82(17):1521-1528.

The expanding clinical and genetic spectrum of ATP1A3-related disorders, Rosewich et al. 82(11):945-955.

Ketogenic diet for adults in super-refactory status epilepticus, Thakur et al. 82(8):665-670.

Anterior interosseous nerve syndrome: Fascicular motor lesions of median nerve trunk, Pham et al. 82(7):598-606.

ASA failure: Does the combination ASA/clopidogrel confer better long-term vascular protection?, Côté et al. 82(5):382-389.

Practical utility of amyloid and FDG-PET in an academic dementia center, Sánchez-Juan et al. 82(3):230-238.

Hypoxic locomotor rehabilitation for incomplete spinal cord injury, Plow and Fehlings 82(2):98-99.

Daily intermittent hypoxia enhances walking after chronic spinal cord injury: A randomized trial, Hayes et al. 82(2):104-113.

Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathy, Shima et al. 82(2):114-118.

 

Neurology® 2013; Vol. 81

Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mututations, Pfeffer et al. 81(24):2073-2081.

Do antiepileptic drugs cause suicidal behavior?, Harden and Meador 81(22):1889-1890.

Temporal trends in new exposure to antiepileptic drug monotherapy and suicide-related behavior, Pugh et al. 81(22):1900-1906.

MRI in acute cerebral ischemia of the young: The Stroke in Young Fabry Patients (sifap1) Study, Fazekas et al. 81(22):1914-1921.

Anterior nucleus of the thalamus: Functional organization and clinical implications, Child and Benarroch 81(21):1869-1876.

Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity, Jack et al. 81(20):1732-1740.

Sensitivity of MRI of the spine compared with CT myelography in orthostatic headache with CSF leak, Starling et al. 81(20):1789-1792.

Autoimmune encephalopathies: Expanding spectrum of GABAB receptor antibody disorders, Carter and Honnorat 81(17):1482-1483.

Encephalitis and GABAB receptor antibodies: Novel findings in a new case series of 20 patients, Höftberger et al. 81(17):1500-1506.

Evidence-based guideline update: Vagus nerve stimulation for the treatment of epilepsy: Report of the Guideline Development Subcommittee of the American Academy of Neurology, Morris et al. 81(16):1453-1459.

Incidence and prevalence of small-fiber neuropathy: A survey in the Netherlands, Peters et al. 81(15):1356-1360.

Imaging markers for Alzheimer disease: Which vs how, Frisoni et al. 81(5):487-500.

Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL, Farrell et al. 81(3):256-263.

Expanding the clinical phenotype of DYT5 mutations: Is multiple system atrophy a possible one?, Ceravolo et al. 81(3):301-302.

 

Neurology® 2013; Vol. 80

Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology, Armstrong et al. 80(22):2065-2069.

Stroke risk after TIA: DWI is only part of the answer, Ceoutts and Cucchiara 80(21):1914-1915.

MRI findings and stroke risk in TIA patients with different symptom durations, Al-Khaled and Eggers 80(21):1920-1926.

Transglutaminase 6 antibodies in the diagnosis of gluten ataxia, Hadjivassiliou et al. 80(19):1740-1745.

 

Neurology® 2012; Vol. 79

Don't stress about it!: Is stress management a disease-modifying therapy for multiple sclerosis?, Heesen and Gold 79(5):398-399.

A randomized trial of stress management for the prevention of new brain lesions in MS, Mohr et al. 79(5):412-419.

Genomic medicine enters the neurology clinic, Coppola and Geschwind 79(2):112-114

Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease, Lattante et al. 79(1):66-72.

 

Neurology® 2012; Vol. 78

Proteinuria and clinical outcomes after ischemic stroke, Kumai et al. 78(24):1909-1915.

Patterns of treatment response in newly diagnosed epilepsy, Brodie et al. 78(20):1548-1554.

Mitochondrial dynamics: General concepts and clinical implications, Milone and Benarroch 78(20):1612-1619.

GABAB receptors: Structure, functions, and clinical implications, Benarroch 78(8):578-584.

Paradoxical worsening of gait with levodopa in Parkinson disease, Chen 78(7):446-447.

On state freezing of gait in Parkinson disease: A paradoxical levodopa-induced complication, Espay et al. 78(7):454-457.

Alzheimer disease: Can the exam predict the pathology?, Swerdlow and Jicha 78(6):374-375.

Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease, Wagner et al. 78(6):379-386.

Predicting outcome of IV thrombolysis–treated ischemic stroke patients: The DRAGON score, Strbian et al. 78(6):427-432.

 

Neurology® 2011; Vol. 77

Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus, Mishra et al. For the SITS and VISTA collaborators 77(21):1866-1872.

Myasthenia gravis with antibodies to MuSK: Another step toward solving mystery?, Evoli and Lindstrom 77(20):1783-1784.

Parkinson disease: The enteric nervous system spills its guts, Derkinderen et al. 77(19):1761-1767.

Encephalitis and antibodies to synaptic and neuronal cell surface proteins, Lancaster et al. 77(2):179-189.

 

Neurology® 2011; Vol. 76

Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy, French et al. On behalf of the RESTORE 1/Study 301 Investigators 76(18):1555-1563.

Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials, Bates 76(Suppl 1):S14-S25.